目的 探究葛根素注射液聯(lián)合鹽酸法舒地爾治療缺血性腦梗死的臨床療效。方法 選取2014年6月-2015年6月廣州市花都區(qū)花山鎮(zhèn)衛(wèi)生院收治的缺血性腦梗死患者84例,按照治療方法的不同分為對照組和治療組,每組各42例。對照組靜脈滴注鹽酸法舒地爾注射液,60 mg加入到250 mL生理鹽水中,1次/d。治療組在對照組治療的基礎(chǔ)上靜脈滴注葛根素注射液,400 mg加入生理鹽水250 mL,1次/d。兩組患者均連續(xù)治療14 d。觀察兩組的臨床療效,同時比較兩組治療前后紅細胞沉降率(ESR)、血細胞比容(HCT)、纖維蛋白原(FIB)、紅細胞聚集指數(shù)(RF)、全血高切黏度(HS)、神經(jīng)功能缺損(NIHSS)評分、血管內(nèi)皮素-1(ET-1)的變化情況。比較兩組不良反應(yīng)發(fā)生情況。結(jié)果 治療后,對照組和治療組的總有效率分別為80.95%、95.24%,兩組比較差異具有統(tǒng)計學(xué)意義(P<0.05)。治療后,兩組ESR、HCT、FIB、RF、HS、NIHSS評分、ET-1均較治療前顯著降低,同組治療前后差異有統(tǒng)計學(xué)意義(P<0.05);且治療組這些觀察指標(biāo)的降低程度優(yōu)于對照組,兩組比較差異有統(tǒng)計學(xué)意義(P<0.05)。對照組和治療組的不良反應(yīng)發(fā)生率分別為9.52%、7.14%;兩組比較差異無統(tǒng)計學(xué)意義。結(jié)論 葛根素注射液聯(lián)合鹽酸法舒地爾治療缺血性腦梗死具有較好的臨床療效,能夠明顯改善患者的血液流變學(xué)狀態(tài),并能顯著降低ET-1的表達,具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical effect of Puterarin Injection combined with fasudil hydrochloride in treatment of ischemic cerebral infarction.Methods Patients (84 cases) with ischemic cerebral infarction in Huashan Township Health Center of Huadu District in Guangzhou from June 2014 to June 2015 were enrolled in this study. According to the different treatment plans, patients were divided into control group (42 cases) and treatment group (42 cases). The patients in the control group were iv administered with Fasudil Hydrochloride Injection, 60 mg added into normal saline 250 mL, once daily. The patients in the treatment group were ivadministered with Puterarin Injection on the basis of control group, 400 mg added into normal saline 250 mL, once daily. The patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and the changes of ESR, HCT, FIB, RF, HS, NIHSS scores, and ET-1 in two groups before and after treatment were compared. The adverse reactions in two groups were compared.Results After treatment, the efficacies in the control and treatment groups were 80.95 and 95.24%, respectively, and there were differences between two groups (P < 0.05). After treatment, ESR, HCT, FIB, RF, HS, NIHSS scores, and ET-1 in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). The incidence of adverse reactions in the control and treatment groups were 9.52% and 7.14%, respectively, and there was no difference between two groups.Conclusion Puterarin Injection combined with fasudil hydrochloride has clinical curative effect in treatment of ischemic cerebral infarction, and can significantly improve hemorheology status, and can significantly reduce the expression of ET-1, which has a certain clinical application value.